1584 studies found for:    melanoma
Show Display Options
Rank Status Study
1 Completed
Has Results
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
2 Recruiting Immunotherapy Study for Patients With Stage IV Melanoma
Conditions: Stage IV Melanoma;   Metastatic Melanoma
Interventions: Drug: HyperAcute®-Melanoma (HAM) Immunotherapy;   Drug: Ipilimumab
3 Active, not recruiting
Has Results
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: melanoma helper peptide vaccine;   Biological: multi-epitope melanoma peptide vaccine;   Biological: sargramostim;   Biological: tetanus peptide melanoma vaccine
4 Unknown  Characterization of the Melanoma-Specific Immune Response
Condition: Melanoma
Intervention:
5 Recruiting Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
Condition: Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib
6 Active, not recruiting Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma
Condition: Melanoma
Intervention: Biological: 4-peptide and 12-peptide melanoma vaccines
7 Active, not recruiting Melanoma Risk-Reduction Among Patients and Family Members
Condition: Melanoma
Interventions: Behavioral: Questionnaire;   Behavioral: Interview
8 Active, not recruiting Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
Condition: Melanoma
Interventions: Biological: melanoma GVAX;   Drug: Cyclophosphamide
9 Terminated
Has Results
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental
Interventions: Drug: DMF5 Melanoma Reactive TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
10 Completed Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma
Condition: Melanoma
Interventions: Drug: low-dose IL-2;   Biological: melanoma vaccine
11 Completed Comparison of Video-Based Versus Written Patient Education on Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Other: Patient Educational Materials
12 Completed Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients
Condition: Melanoma
Intervention: Other: biological collection
13 Unknown  Melanoma Margins Excision Trial
Condition: Melanoma
Intervention: Procedure: Surgical Excision Margin
14 Active, not recruiting Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
Conditions: Intraocular Melanoma;   Melanoma (Skin)
Interventions: Biological: IFA;   Biological: 6MHP;   Biological: GM-CSF
15 Active, not recruiting Vaccination Plus Ontak in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: 4-peptide melanoma vaccine;   Drug: 4-peptide melanoma vaccine plus Ontak;   Drug: ontak
16 Terminated Study for the Evaluation of Vemurafenib ( Zelboraf® ) and Ipilimumab ( Yervoy® ) in Combination With DNE3 Therapy to Patients With Metastatic Melanoma
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Drug: Vemurafenib 960 mg tablet by mouth (oral) twice daily;   Drug: Ipilimumab 10 mg/kg Intravenous (IV) injection;   Biological: DNE3 0.2 g/kg of body weight
17 Completed
Has Results
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
Condition: Melanoma
Interventions: Drug: Glycoprotein 100 (GP100): 209-217 (210M);   Drug: Interleukin-2 (IL-2);   Drug: Montanide ISA 51;   Drug: Melanoma antigen recognized by T-cells (MART)-1: 27-35;   Drug: 27-35 (27L): melanoma antigen recognized by T-cells (MART)-1;   Drug: melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)
18 Completed Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Extraocular Extension Melanoma;   Iris Melanoma;   Metastatic Intraocular Melanoma;   Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIC Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Biological: gp100 antigen;   Biological: tyrosinase peptide;   Biological: recombinant MAGE-3.1 antigen;   Biological: multi-epitope melanoma peptide vaccine;   Biological: incomplete Freund's adjuvant;   Drug: Montanide ISA 51 VG;   Drug: agatolimod sodium;   Other: laboratory biomarker analysis
19 Unknown  Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: incomplete Freund's adjuvant;   Biological: melanoma helper peptide vaccine;   Biological: multi-epitope melanoma peptide vaccine;   Biological: tetanus toxoid helper peptide;   Drug: cyclophosphamide
20 Not yet recruiting Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma
Condition: Metastatic Melanoma to the Groin Lymph Nodes
Interventions: Procedure: Inguinal Lymphadenectomy;   Procedure: Ilio-inguinal Lymphadenectomy

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years